As of today (2025-07-03), Insulet's share price is $301.05.
Insulet's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $3.80. Hence, Insulet's Price-to-Free-Cash-Flow Ratio for today is 79.33.
The historical rank and industry rank for Insulet's Price-to-Free-Cash-Flow or its related term are showing as below:
PODD'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 62.83 Med: 89.8 Max: 2698.57
Current: 80.04
During the past 13 years, Insulet's highest Price-to-Free-Cash-Flow Ratio was 2698.57. The lowest was 62.83. And the median was 89.80.
PODD's Price-to-Free-Cash-Flow is ranked worse than 81.23% of 373
companies
in the Medical Devices & Instruments industry
Industry Median: 28.88
vs PODD: 80.04
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Insulet was 105.20% per year.
During the past 13 years, Insulet's highest 3-Year average Free Cash Flow per Share Growth Rate was 67.00% per year. The lowest was -137.90% per year. And the median was 22.10% per year.
Insulet Price-to-Free-Cash-Flow Historical Data
The historical data trend for Insulet's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Insulet's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Insulet's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Insulet's Price-to-Free-Cash-Flow falls into.
Insulet's Share Price of today is $301.05. Insulet's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Insulet Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Insulet's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your 